This prognostic diversity is most evident in the cytogenetic intermediate-risk AML subgroup (IR-AML), which is now commonly subdivided into molecular prognostic categories according to the mutational status of NPM1, internal tandem duplication of FLT3 (FLT3-ITD), and CEBPA [1–3]. This evidence concerns the gene CEBPA and acute myeloid leukemia.